Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia

Ronen R. Leker*, Esther Shohami, Oded Abramsky, Haim Ovadia

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

The permanent middle cerebral artery occlusion (PMCAO) model was used to investigate the cerebroprotective effects of the synthetic cannabinoid, dexanabinol (HU-211). Dexanabinol is a noncompetitive N-methyl-D-aspartate antagonist, with antioxidant and anti-TNFα properties. Twenty hypertensive rats were subjected to PMCAO. Eight were given 4 mg/kg dexanabinol, i.v, 1 h after PMCAO, eight received vehicle and four were not injected. Five rats underwent sham surgery. Infarct volumes were assessed, as well as TNFα concentrations and NOS activity in brain homogenates. Dexanabinol significantly decreased infarct volumes. It also significantly lowered TNFα levels in the ipsilateral hemisphere although not to the level of sham operated rats. No effect could be demonstrated on NOS activity. In conclusion, dexanabinol may be a pluripotent cerebroprotective agent.

Original languageEnglish
Pages (from-to)114-119
Number of pages6
JournalJournal of the Neurological Sciences
Volume162
Issue number2
DOIs
StatePublished - 15 Jan 1999

Keywords

  • Dexanabinol
  • Ischemia
  • Nitric oxide synthase
  • Stroke
  • TNFα

Fingerprint

Dive into the research topics of 'Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia'. Together they form a unique fingerprint.

Cite this